Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
EDIT 
Editas Medicine Inc (EDIT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: EDIT (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $4
1 Year Target Price $4
| 4 | Strong Buy |
| 1 | Buy |
| 8 | Hold |
| 2 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 18.62% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 356.08M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 15 | Beta 2.18 | 52 Weeks Range 0.91 - 4.54 | Updated Date 10/18/2025 |
52 Weeks Range 0.91 - 4.54 | Updated Date 10/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.84 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -711.63% |
Management Effectiveness
Return on Assets (TTM) -33.76% | Return on Equity (TTM) -188.58% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 192423437 | Price to Sales(TTM) 9.15 |
Enterprise Value 192423437 | Price to Sales(TTM) 9.15 | ||
Enterprise Value to Revenue 4.95 | Enterprise Value to EBITDA -1.36 | Shares Outstanding 89920164 | Shares Floating 89572173 |
Shares Outstanding 89920164 | Shares Floating 89572173 | ||
Percent Insiders 0.3 | Percent Institutions 49.05 |
Upturn AI SWOT
Editas Medicine Inc
Company Overview
History and Background
Editas Medicine Inc. was founded in 2013. It is a clinical-stage genome editing company focused on developing transformative medicines to treat serious diseases. They utilize CRISPR technology.
Core Business Areas
- Genome Editing Therapeutics: Development and commercialization of CRISPR-based therapies for genetic diseases.
Leadership and Structure
The leadership team includes Gilmore O'Neill, M.D. as President and CEO. The organizational structure is typical of a biotechnology company, with research, development, and commercial functions.
Top Products and Market Share
Key Offerings
- EDIT-101 (Allergan collaboration): An experimental AAV5-delivered CRISPR therapy for LCA10, a form of inherited blindness. It is in clinical trials. Market share data unavailable due to being in clinical stage. Competitors include MeiraGTx, ProQR Therapeutics, and Gensight Biologics.
- EDIT-301: An experimental CRISPR therapy for sickle cell disease and beta-thalassemia. It is in clinical trials. Market share data unavailable due to being in clinical stage. Competitors include Vertex Pharmaceuticals and CRISPR Therapeutics (CTX001/exagamglogene autotemcel).
Market Dynamics
Industry Overview
The genome editing industry is rapidly evolving, with significant potential for treating genetic diseases. It is highly competitive and regulated.
Positioning
Editas Medicine Inc. is a leader in the CRISPR-based genome editing space. They are focused on developing therapies for severe genetic diseases, giving them a strong advantage.
Total Addressable Market (TAM)
The TAM for gene editing therapies is estimated to be in the tens of billions of dollars. Editas is positioned well, though in early stages of capitalizing on this TAM.
Upturn SWOT Analysis
Strengths
- Pioneering CRISPR technology
- Strong intellectual property portfolio
- Experienced leadership team
- Strategic partnerships
Weaknesses
- High research and development costs
- Regulatory hurdles
- Clinical trial risks
- Reliance on strategic collaborations
Opportunities
- Expansion into new therapeutic areas
- Advancements in CRISPR technology
- Increasing regulatory acceptance of gene editing therapies
- Potential for strategic acquisitions or partnerships
Threats
- Competition from other gene editing companies
- Unforeseen side effects of CRISPR therapies
- Ethical concerns surrounding gene editing
- Patent disputes
Competitors and Market Share
Key Competitors
- CRSP
- NTLA
- BEAM
Competitive Landscape
Editas faces strong competition from other gene editing companies. Their competitive advantage lies in their CRISPR technology and their focus on specific genetic diseases.
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily in terms of research and development, with increasing investments in clinical programs.
Future Projections: Future growth is dependent on the successful completion of clinical trials and regulatory approval of their therapies. Analyst estimates vary depending on trial outcomes.
Recent Initiatives: Focusing on advancing EDIT-301 program for sickle cell disease and beta-thalassemia, optimization of their CRISPR technology, and securing new strategic partnerships.
Summary
Editas Medicine is a pioneering CRISPR-based genome editing company with potential transformative therapies. It's in clinical stages and requires careful monitoring of trial data. Their strength lies in CRISPR technology, but they need to navigate regulatory hurdles and competition. Future growth depends on successful trial outcomes.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Press releases
- Editas Medicine Inc. website
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on thorough research and consultation with a financial professional. Market share data is an estimate
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Editas Medicine Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2016-02-03 | President, CEO & Director Dr. Gilmore O'Neill M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 246 | Website https://www.editasmedicine.com |
Full time employees 246 | Website https://www.editasmedicine.com | ||
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.